RESULTS

CONCLUSIONS
◆ Given the similar survival benefits, these findings demonstrate that AA is cost-saving compared with ENZ for the treatment of mCRPC post-docetaxel in the US. 
METHODS
◆ A survival-based Markov cohort model consisting of 3 health states (ie, progressionfree, progressed, and death) was developed to project cost-effectiveness over a 10-year period ( Figure 1 ). ◆ Progression between states was determined by efficacy data for overall survival (OS) and radiographic progression-free survival (rPFS). Progression did not include deaths. ◆ As the relative efficacy for AA and ENZ has not yet been established in a head-to-head trial, an indirect treatment comparison (ITC) was conducted using the pivotal phase 3 trials for AA 1 and ENZ.
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-Since AA + prednisone was compared with placebo + prednisone in Study COU-AA-301, the on-corticosteroids subgroup in the AFFIRM trial (for ENZ) was used to ensure a common comparator in the ITC.
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◆ In the ITC, with prednisone as the common comparator, the hazard ratio for OS of AA versus ENZ was 0.95 (95% CI: 0.71-1.26). ◆ Given differences in the definition of rPFS between trials, this outcome was not included in the ITC.
-To be conservative in the modeled analysis, rPFS was assumed to be equivalent between the 2 comparators. ◆ Model state utilities were derived from mapping the FACT-P to the EQ-5D using a validated algorithm.
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◆ Disutility associated with adverse events (AEs) was obtained from a review of the literature. ◆ Outcomes and costs were discounted at 3% per annum.
-Costs were represented in 2013 US dollars. ◆ Drug acquisition costs in the United States (US) were used in the analysis (ENZ was approved only in the US at the time of analysis). Table and Physician Fee Schedule. ◆ The model additionally considered the grade 3/4 AE rates and associated costs for the active and subsequent treatments. ◆ One-way sensitivity analyses were performed on all utility and cost values incorporated into the model (Table 1) . 
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